In Vitro Evaluation Of Anti-Cancer Potential Of A3 Adenosine Receptor Agonist On A549 Human Lung Cancer Cell Line

Simple item page
dc.contributor.authorSolanki, N. D.en_US
dc.contributor.authorPatel, A.en_US
dc.contributor.authorPatel, L.en_US
dc.date.accessioned2020-09-24T08:00:48Z
dc.date.available2020-09-24T08:00:48Z
dc.date.issued2019-06
dc.description.abstractObjective: The objective of this study was to evaluate the cytotoxic potential of A3AR agonist (ABMECA) against human lung cancer cell line A549 by using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay. Methods: Adenocarcinoma cell line A549 was used to assess MTT based cells viability. In vitro cytotoxic activity was evaluated for 3 different concentration of doxorubicin and A3AR by MTT cytotoxicity assay. Cytotoxicity assay carried out for 3 consecutive days that involves culturing cells into Dulbecco’s MEM medium modified with 10% FBS for 24 h then treatment with different dose of standard and test drug with incubation period of 24 h followed by treatment with MTT for estimation of cytotoxicity and finally, optical density (OD) was measured at 570-630 nm. Results: Different concentration of doxorubicin (1, 5, 10 µM) and ABMECA (10-6M, 10-5M and 10-4M) shown dose-dependent cytotoxicity. There was a significant decrease (p<0.05) in cell viability in both doxorubicin and ABMECA concentration in a dose-dependent manner. This study may guide further for in vivo evaluation of test drug in the lung cancer model. Conclusion: A3 Adenosine Receptor agonist could be potential moiety for the treatment of lung cancer and it would require in vivo study for further research.en_US
dc.identifier.affiliationsDepartment of Pharmacology, Ramanbhai Patel College of Pharmacy, Charusat University, Changa, Gujaraten_US
dc.identifier.affiliationsCBCC Global research India, Ahmedabad.en_US
dc.identifier.affiliationsDepartment of Pharmacology, Ramanbhai Patel College of Pharmacy, Charusat University, Changa, Gujaraten_US
dc.identifier.citationSolanki N. D., Patel A., Patel L.. In Vitro Evaluation Of Anti-Cancer Potential Of A3 Adenosine Receptor Agonist On A549 Human Lung Cancer Cell Line. International Journal of Pharmacy and Pharmaceutical Sciences. 2019 Jun; 11(6): 106-108en_US
dc.identifier.issn0975-1491
dc.identifier.issn2656-0097
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/205816
dc.languageenen_US
dc.publisherInnovare Academic Sciences Pvt. Ltd.en_US
dc.relation.issuenumber6en_US
dc.relation.volume11en_US
dc.source.urihttps://doi.org/10.22159/ijpps.2019v11i6.30863en_US
dc.subjectA549 cell lineen_US
dc.subjectAdenosineen_US
dc.subjectDoxorubicinen_US
dc.subjectMTT assayen_US
dc.subjectLung canceren_US
dc.titleIn Vitro Evaluation Of Anti-Cancer Potential Of A3 Adenosine Receptor Agonist On A549 Human Lung Cancer Cell Lineen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijpps2019v11n6p106.pdf
Size:
327.99 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Pharmacy and Pharmaceutical Sciences